MedTrace Logo

Revaccination With Influenza Vaccine GSK1247446A

NCT00545025 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 243

Last updated 2019-06-26

Study results available
· View outcomes & findings →

Summary

The protocol is designed to demonstrate the safety of influenza vaccine GSK1247446A after revaccination.

Conditions

Interventions

BIOLOGICAL

Influenza Vaccine GSK1247446A

Single dose, Intramuscular injection

BIOLOGICAL

Fluarix™

Single dose, Intramuscular injection

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-15
Primary Completion
2007-12-12
Completion
2007-12-12

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00545025 on ClinicalTrials.gov